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Abstract
Objective: To evaluate the relation between yogurt consumption as well as cheese, milk, and 
total dairy, and high blood pressure (HBP) in two Nurses’ Health Study cohorts (NHS, n=69,298), 
NHS II (n=84,368) and the Health Professionals Follow-Up Study (HPFS, n=30,512).
Methods: NHS, NHS II, and HPFS participants were followed for incident HBP for up to 30, 20, 
and 24 years, respectively. Hazard ratios were calculated using time-dependent multivariate-
adjusted Cox proportional hazards models. Pooled risk estimates were derived from fixed effects 
meta-analyses.
Results: Participants consuming ≥5 servings/week (vs. <1 serving/month) of yogurt in NHS, 
NHS II, and HPFS had 19% (95% CI:0.75–0.87), 17% (95% CI:0.77–0.90), and 6% (95% CI: 
0.83–1.07) lower HBP risks, respectively. In pooled analyses of these cohorts, higher yogurt 
consumption was linked with 16% (95% CI:0.80–0.88) lower HBP risk; higher total dairy (3–<6 
vs. <0.5 servings/day), milk (2–<6/day vs. <4/week) and cheese (1–4/day vs. <1/week) were 
associated with 16% (95% CI:0.81–0.87), 12% (95% CI:0.86–0.90) and 6% (95% CI:0.90–0.97) 
lower HBP risks, respectively. After controlling for BMI as a possible causal intermediate, total 
dairy, yogurt, milk, and cheese were associated with 13%, 10%, 8%, and 8% lower HBP risks, 
respectively. The combination of higher yogurt intake and higher DASH (“Dietary Approaches to 
Stop Hypertension”) diet scores was associated with 30% (95% CI:0.66–0.75) lower HBP risk 
compared with lower levels of both factors.
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Conclusion: Higher total dairy intake, especially in the form of yogurt, was associated with 
lower risk of incident HBP in middle-aged and older adult men and women.
Keywords
nutrition; long-term diet; dairy; yogurt; epidemiology; Dietary Approaches to Stop Hypertension; 
fermented foods
INTRODUCTION
About 80 million American adults have high blood pressure (HBP) [1], resulting in more 
than 65,000 deaths annually [2]. The beneficial effects of dairy consumption on BP was 
demonstrated in the “Dietary Approaches to Stop Hypertension” (DASH) randomized 
clinical trial wherein the greatest BP-lowering effects were found in the combined dietary 
intervention arm focusing on increasing intakes of low-fat dairy and fruits and vegetables 
(FV) [3]. Subsequent longitudinal studies found dairy intake to be inversely associated with 
mean BP and HBP risk in normal-weight and overweight adults [4–6]. Reviews and meta-
analyses have generally confirmed these earlier results [7,8]. The 2010 Dietary Guidelines 
for Americans [9] cited moderate evidence for a beneficial effect of dairy consumption on 
BP, as well as cardiovascular disease and type 2 diabetes mellitus (T2DM) risk.
Yogurt is a form of dairy with high concentrations of casein and whey proteins, as well as 
calcium, magnesium, and potassium [10], all of which have been linked with BP-lowering 
effects in animal studies and some observational and experimental human studies [11]. 
Findings from the few available longitudinal studies examining the direct effects of yogurt 
intake on BP have been inconclusive [12–14]. Relatively low levels of yogurt intake in most 
studies may limit the statistical power to capture the true effect of clinically meaningful 
amounts of yogurt consumption.
This study aims to estimate the associations of long-term yogurt intake and other forms of 
dairy on risk of incident HBP among over 180,000 middle-aged women and men followed 
for 20–30 years in three prospective cohorts: The Nurses’ Health Study (NHS), Nurses’ 
Health Study II (NHS II), and the Health Professionals Follow-Up Study (HPFS).
METHODS
Study Sample
The NHS enrolled 121,741 female registered nurses, initially 30–55 years of age in 1976. 
The NHS II was initiated in 1989 with enrollment of 116,430 female registered nurses ages 
25–42 years. The HPFS began in 1986 with 51,529 men ages 40–75 years enrolled from 
various medical fields. Follow-up in all cohorts was conducted via questionnaire. Medical 
and lifestyle data were collected at baseline and biennially thereafter.
For the current analyses, men and women with baseline diagnoses of prevalent HBP, angina, 
stroke, myocardial infarction (MI), revascularization procedures, diabetes (type 1, type 2, 
gestational), or cancer were excluded. Additional exclusions included: participants who left 
>70 of 131 items blank on the baseline food frequency questionnaire (FFQ), unusual total 
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energy intakes (<500 or >3,500 kcals/d for women and <800 or >4,200 kcals/d for men), 
missing follow-up HBP information, missing total dairy or unusually high intakes of total 
dairy (≥6 s/d), cheese (>4 s/d), or milk (≥6 s/d). After exclusions, data from 69,298 NHS, 
84,368 NHS II, and 30,512 HPFS participants were included in the current analyses which 
were approved by the Institutional Review Board of the Boston University School of 
Medicine.
Assessment of Dairy and Yogurt Consumption
At baseline and follow-up exams, participants were asked to report usual intake in the past 
year of various foods including all dairy products, using validated, semi-quantitative FFQs 
[15]. Response categories ranged from “never-<1/month” to “6+ per day”. Reported intakes 
were converted to continuous values by assigning the midpoint value of the chosen response 
category for each item. For these analyses, FFQ serving sizes were converted to standard 
United States Department of Agriculture MyPyramid serving sizes [16]. Using the 
MyPyramid definition of a dairy product, cream cheese, butter, and cream were excluded 
from the total dairy variable [16]. Thus, total dairy intake included: milk (skim, low-fat, 
whole), ice cream, sherbet/frozen yogurt, cheese (cottage, ricotta, hard, sliced), and yogurt 
(all types).
High Blood Pressure Outcome Ascertainment
At every biennial questionnaire, participants were asked to self-report incident physician 
diagnoses of HBP, a method of self-report has been previously validated in the NHS and 
HPFS cohorts [17–19].
Covariate Assessment
Data on chronic disease risk factors including weight, age, physical activity, smoking, and 
family history of HBP were gathered biennially. Height (in meters) and weight (kilograms) 
were used to calculate BMI (weight/height2). Total metabolic equivalent (MET) hours of 
activity per week (MET-hrs/week) were calculated based on participants’ self-reported 
average weekly time (frequency and duration) spent in activities of variable intensity [20–
22].
Since yogurt has been associated with an overall diet quality [23], a previously-described 
DASH diet score was explored as a potential modifier of the association between yogurt 
intake and HBP [24]. Also, since dairy intake is a component of the DASH score, the 
relevant dairy foods were dropped from the calculation of the score for each analysis. For 
example, models examining the combination of yogurt intake and a DASH score included 
the following variables in the calculation of the DASH score: fruits; vegetables; nuts and 
legumes; whole grains; red and processed meats; sugar-sweetened beverages; sodium; and 
total dairy minus yogurt [24]. Yogurt was also examined in combination with other 
individual dietary factors linked with blood pressure such as fruits and vegetables, fiber, 
whole grains, sodium, potassium, magnesium, and the sodium to potassium ratio. The 
DASH score was used in the final stratified models as it was associated with the most 
consistent estimates of effect and had the least associated variability.
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Statistical Analysis
The dietary exposure period began at the time of first dietary assessment. Follow-up for 
incident HBP started at the end of that exam and continued until the first of the following 
censoring events: incident HBP, death, lost to follow-up, or end of follow-up for these 
analyses (30 June 2010 for NHS, 30 June 2009 for NHS II, and 31 January 2010 for HPFS).
To estimate long-term dairy consumption and to minimize the possibility of reverse 
causation, average intake for each dairy food was calculated as a cumulative average of all 
reported dietary intakes from the baseline FFQ to the exam before the first censoring event. 
Dietary intakes were weighted equally in calculating cumulative average intakes [25]. 
Updating of intake was stopped in the event of an interim MI, revascularization, stroke, 
diabetes, or cancer, as these events may lead to changes in usual dairy intake [25,26]. For 
missing dietary data, intakes were carried forward from the last non-missing exam to the 
next reported intake. To compare the effects of short-term dairy intake with those associated 
with cumulative average intakes, we also estimated the association between the most 
recently updated dairy intakes and incident HBP (supplemental table 1).
Each dairy food was categorized using cutoff values chosen to optimize analytical power 
while also reflecting intakes that were easily interpretable and applicable to daily 
recommendations and existing FFQ categories. For example, yogurt intake was categorized 
as: <1 serving/month (s/mo), 1 s/mo–<1 serving/week (s/wk), 1–<2 s/wk, 2–<5 s/wk, and ≥5 
s/wk. Using sensitivity analyses, yogurt intake was then collapsed into three categories: <1 
s/mo (low), 1 s/mo–<5 s/wk (moderate), ≥5 s/wk (high); these intake groups were then 
cross-classified with tertiles of the DASH diet score to explore possible combined 
associations between high yogurt consumption and the DASH score.
Rates of HBP occurrence were calculated in each category of dairy intake. Time-dependent 
Cox proportional hazards models were used to estimate the hazard ratios (HR) and the 95% 
confidence intervals (CI) for risk of incident HBP according to intake. Factors retained in the 
final multivariable models were those that confounded the estimated effect of dairy and HBP 
in at least some of the models by ≥ 10%. These included age, race, smoking, family history 
of HBP, physical activity, intakes of total energy, total protein, FV, and other dairy foods 
(e.g., yogurt models controlled for cheese and milk). Finally, updated BMI was added in 
separate models as it may function as either a potential confounder or a causal intermediate 
between dairy and HBP risk. Other potential confounders that were explored included 
family history of diabetes, MI, or hypercholesterolemia, pack-years of cigarettes smoked, 
alcohol intake, post-menopausal hormone use, oral contraceptive use (in NHS), aspirin and 
multivitamin use, and cumulative average intakes of the following dietary factors: 
carbohydrates, total fat and fat subtypes (saturated, monounsaturated, polyunsaturated, 
omega-3, trans fatty acids), protein (animal, and plant), whole grains, total fiber cereal fiber, 
nuts, sugar-sweetened beverages, potatoes, beans, red and processed meats, vitamin D, 
sodium, potassium, calcium, and magnesium. These variables were dropped from the final 
model as they had no effect on the HRs.
All analyses were initially conducted for each cohort separately and then pooled using fixed-
effects meta-analyses. To test for linear trend, a regression model was used to examine the 
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shape of the relation across categories of dairy intake and HBP. The proportional hazards 
assumption was tested using a likelihood ratio test comparing the model with and without an 
interaction term between time period and each dairy exposure category. All statistical 
analyses were carried out using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA).
RESULTS
There were 82,382 total incident HBP cases in the three cohorts: 41,934 during 30 years of 
follow-up in NHS; 26,282 during 20 years in NHS II, and 14,166 during 24 years in the 
HPFS. Mean baseline ages in the three cohorts were 44.6, 35.8, and 50.7 years, respectively.
Age-adjusted baseline demographic characteristics according to yogurt intake categories 
(frequency of consuming 1 cup) in all three cohorts are shown in Table 1. Those with the 
highest yogurt intakes were more active, had lower BMIs, were less likely to smoke, and had 
higher diet quality as reflected in higher DASH diet scores.
Table 2 shows the association between total dairy intake and HBP risk in the three cohorts. 
After adjusting for age, race, physical activity, smoking, HBP family history, and intakes of 
FV, total protein and energy, those in the NHS, NHS II, and HPFS cohorts who consumed 
≥3 s/d (vs. <0.5 s/d) of total dairy had 13% (95% CI: 0.83–0.91), 25% (95% CI: 0.70–0.79), 
and 7% (95% CI: 0.86–1.00) lower risks of HBP, respectively. There were statistically 
significant inverse linear trends in all three cohorts. Addition of BMI to the models did not 
significantly change the beneficial associations for all three cohorts: NHS - 11%, NHS II - 
19%, HPFS - 9%. The rates of HBP show that the younger women consuming ≥3 s/day of 
dairy in NHS II had 637 fewer cases of incident HBP (per 100,000 py) than those 
consuming <0.5 s/day. In contrast, HPFS men (who were ≥15 years older) had only 166 
fewer cases per 100,000 person years (py) associated with higher dairy intakes.
Table 3 shows the impact of long-term yogurt consumption on HBP risk. Those who 
regularly consumed ≥5 s/wk (vs. <1 s/mo) of yogurt in the NHS, NHS II, and HPFS cohorts, 
respectively had 19% (95% CI: 0.75–0.87), 17% (95% CI: 0.77–0.90), and 6% (95% CI: 
0.83–1.07) lower risks of HBP. Addition of BMI to the models did not significantly change 
the HRs for all three cohorts: NHS - 0.87, NHS II - 0.89, HPFS - 1.01. The HBP rate 
differences between the highest and lowest categories of yogurt intake were similar across 
the three cohorts (453, 374, and 446/100,000 py, respectively).
Table 4 shows fixed effects pooled analyses results examining HBP risk associated with 
intakes of total dairy, yogurt, cheese, and milk in the combined cohorts. Although the hazard 
ratios were not markedly different in the three cohorts, the I2 values indicate that there was 
heterogeneity across the cohorts for milk and cheese intakes but not for yogurt. Overall, 
consuming ≥3 s/d of dairy (vs. <0.5 s/day) was associated with a 16% (95% CI: 0.81–0.87) 
lower HBP risk. Regular yogurt intake (≥5 s/wk vs. <1 s/mo) was linked with a 16% lower 
HBP risk. Adding BMI to the multivariable models led to little attenuation of the pooled 
HRs. HBP incidence rates among those with the lowest intakes of cheese, milk, and yogurt 
were 2507, 2593, and 2594 cases per 100,000 py, respectively. Increasing intakes (to the 
highest intake categories) was associated with reductions in these incidence rates by 325, 
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251, and 601 cases per 100,000 py, for cheese, milk, and yogurt, respectively. Finally, the 
linear model results found an 18% (95% CI: 0.78–0.85) lower HBP risk associated with each 
additional serving of yogurt per day compared with lower risk reductions for other forms of 
dairy. Results using the most recent dairy exposures (not shown) yielded similar results 
compared to using cumulative average intakes.
Figure 1 and supplemental Table 2 illustrates the combined associations of yogurt intake and 
the DASH diet score on HBP risk from a pooled analysis, adjusting for age, race, physical 
activity, total protein, energy, smoking, and HBP family history. Compared with those who 
had low yogurt intakes and a low DASH diet score (the referent group), those who had both 
a higher DASH diet score (highest tertile) and consumed ≥5 s/wk of yogurt had a 30% lower 
HBP risk (95% CI: 0.66–0.75). In contrast, the highest DASH score alone led to only a 19% 
(95% CI: 0.79–0.83) lower HBP risk among those who consumed yogurt less than once per 
week.
DISCUSSION
Across all three cohorts, higher intakes of total dairy, and particularly yogurt, were 
associated with lower risks of incident HBP. Data from each cohort separately showed that 
total dairy consumption was more strongly associated with a lower HBP in the cohort of 
younger women (NHS II) than in the cohort of older men (HPFS). The associations between 
yogurt consumption and HBP risk were also weaker in the HPFS cohort which could be due 
inherent differences between the cohorts such as age or other diet and lifestyle factors. In 
addition, there were proportionately fewer men in the highest yogurt intake category, in 
which yogurt intakes were lower in men than in women.
Participants who consumed the most yogurt tended to have healthier diets overall as 
measured by a DASH diet score. These results suggest a combined positive association of 
yogurt consumption with a DASH diet in that participants in the highest category on both 
factors had lower risks of HBP. Previous analyses in the Framingham Offspring and Third 
Generation cohorts found that yogurt consumers (vs. non-consumers) tended to have lower 
cardiometabolic risks including HBP, elevated triglycerides and glucose, and insulin 
resistance even after adjusting for diet quality [23]. Another Framingham analysis found that 
consuming ≥1 s/wk of yogurt was associated with lower systolic BP levels and HBP risk 
over 10 years of follow-up [12]. Some but not all other studies have also found yogurt 
consumption to be associated with reductions in cardiometabolic risk (including BP) [27–
31], although most studies have had too few participants who consumed yogurt regularly to 
evaluate long-term effects.
Consistent with other studies [7,13,32], our results provide further support for current 
Dietary Guidelines promoting dairy intake [33] and also support the beneficial effects seen 
in earlier DASH diet trials [3,34]. Participants in this study consuming 3–6 s/d of dairy had a 
16% lower risk of developing HBP. These results are consistent with longitudinal data from 
the Framingham Offspring Study [12], ARIC [13], and middle-aged adults in a French 
cohort [35]. A study of the general Dutch population found no consistent effect of total dairy 
but a trend toward lower risks of incident hypertension associated with low-fat dairy [36]. In 
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the general British population, total dairy was associated with a weak, but non-statistically 
significant trend toward lower hypertension risk [37].
We observed a small inverse association between cheese intake and HBP risk in our 
analyses. In a recent review of full-fat dairy products, Astrup concluded that cheese 
consumption was not associated with adverse effects on metabolic health, including BP [38]. 
A meta-analysis of four studies also found no association between cheese consumption and 
elevated BP [7].
The nutrient composition of dairy is one of several possible mechanisms that may benefit 
BP. Dairy is a source of potassium, for example, which has been shown to lower BP [39] in a 
dose-response manner among both normotensive and hypertensive individuals through its 
effects on smooth muscle relaxation and vasodilation.
Yogurt is made through fermentation, in which biologically active peptides, such as 
isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), are formed when milk 
proteins are catalyzed by proteolytic lactic acid bacteria, such as Lactobacillus helveticus 
[40]. IPP and VPP have been shown to promote antihypertensive effects by inhibiting 
angiotensin-converting enzyme (ACE), a key regulator of BP, fluid, and electrolyte balance 
[41]. These effects have been shown in-vitro [42] and in spontaneously hypertensive rats 
(SHR) [43]. In one study of SHR, investigators found that while supplemental IPP and VPP 
lowered BP, water supplemented with potassium, calcium, magnesium, and sodium also 
lowered BP. However, the greatest lowering of BP was seen among rats fed fermented milk 
[44]. Finally, in humans, a meta-analysis of 14 randomized feeding trials of probiotic milk 
interventions, found modest overall reductions in systolic BP (3.10 mmHg) and diastolic BP 
(1.09 mmHg) [45] , with a stronger effect (systolic BP, 3.98 mmHg) in hypertensive 
individuals.
Yogurt is also a rich source of both calcium and vitamin D, which have been shown to work 
together to in vascular smooth muscle cells to regulate BP via regulation of intracellular 
calcium concentrations[46,47]. In-vitro studies have also shown beneficial effects of these 
nutrients on inflammatory and atherosclerotic agents in hypertensive rats[48–50] but further 
studies in humans are needed to test these potential mechanisms.
In the current study, individuals who consumed more yogurt (and more dairy) also 
consumed less red and processed meat, sugar-sweetened beverages, refined carbohydrates, 
and added sugars. Therefore, the observed reduced risk of HBP associated with dairy and 
yogurt intakes could partly result from a replacement effect. Yogurt may be a marker of a 
healthy lifestyle and the observed inverse associations may be due to residual confounding 
with imperfect adjustment for other factors. Yogurt may support weight maintenance during 
the middle-adult years, thus indirectly benefitting BP by lessening aging-related weight gain 
[51]. Previous analyses in these same cohorts have shown an inverse association between 
yogurt consumption and weight gain while other dairy foods did not appear to have 
significant effects on weight [27]. The addition of BMI as a potential causal intermediate in 
our multivariable model partially attenuated the results.
BUENDIA et al. Page 7
J Hypertens. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our study has several important strengths including its large sample size that enabled us to 
categorize the participants more precisely. The high follow-up rates and availability of 
repeated measures of dietary intake, demographic and lifestyle variables are also important 
strengths. To our knowledge, this is the first longitudinal study with sufficient power to 
estimate the long-term dose-response relation of usual yogurt intake and incident HBP.
Our study also has some limitations. All three cohorts were predominantly Caucasian. While 
the homogeneity of race, education and socioeconomic status may help to reduce 
confounding, our results may not be generalized to other populations. There is strong 
evidence, for instance, of racial differences in HBP risk in the literature [52]. Another 
limitation relates to the use of FFQs, which are prone to a certain degree of measurement 
error. However, yogurt is usually eaten as an individual food and may be less susceptible to 
biased reporting and errors associated with the reporting of mixed dishes [53]. Finally, data 
on yogurt type were not available making it impossible to examine the specific effects of 
yogurt’s protein or probiotic content.
Some of the current pooled analyses had high levels of heterogeneity. This could be due to 
the inherent differences among the cohorts in terms of various BP-related risk factors such 
as sex and age (mean baseline ages were 45, 36, and 52 years in the NHS, NHS II, and 
HPFS cohorts, respectively). Additionally, men have a higher risk of HBP than women until 
age 45, while older women have a higher HBP risk than men [54].
Based on the results of the current study, we conclude that higher total dairy intake 
especially in the form of yogurt was associated with a lower risk of developing HBP during 
the middle adult years. This association was particularly strong among adults with a 
generally healthy diet pattern.
Supplementary Material
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Figure 1. 
Pooled analysis of yogurt servings per week cross-classified with tertiles of a DASH diet 
score and risk of incident hypertension. Yogurt intake servings were classified into three 
categories of intake reflecting low, medium, and high intakes. DASH diet score were 
classified using tertiles of the score across the three cohorts. Analyses were adjusted for age, 
race, physical activity, energy intake, smoking, and family history of HBP.
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